224 related articles for article (PubMed ID: 23460379)
41. Aminoglycoside use in paediatric febrile neutropenia - Outcomes from a nationwide prospective cohort study.
McMullan BJ; Haeusler GM; Hall L; Cooley L; Stewardson AJ; Blyth CC; Jones CA; Konecny P; Babl FE; Mechinaud F; Thursky K;
PLoS One; 2020; 15(9):e0238787. PubMed ID: 32936822
[TBL] [Abstract][Full Text] [Related]
42. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).
Aapro M; Bokemeyer C; Ludwig H; Gascón P; Boccadoro M; Denhaerynck K; Gorray M; Krendyukov A; MacDonald K; Abraham I
J Geriatr Oncol; 2017 Mar; 8(2):86-95. PubMed ID: 27829539
[TBL] [Abstract][Full Text] [Related]
43. Colony stimulating factors for chemotherapy induced febrile neutropenia.
Clark OA; Lyman G; Castro AA; Clark LG; Djulbegovic B
Cochrane Database Syst Rev; 2003; (3):CD003039. PubMed ID: 12917942
[TBL] [Abstract][Full Text] [Related]
44. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
[TBL] [Abstract][Full Text] [Related]
45. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients.
Mitchell PL; Morland B; Stevens MC; Dick G; Easlea D; Meyer LC; Pinkerton CR
J Clin Oncol; 1997 Mar; 15(3):1163-70. PubMed ID: 9060560
[TBL] [Abstract][Full Text] [Related]
46. Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy.
Chia VM; Page JH; Rodriguez R; Yang SJ; Huynh J; Chao C
Breast Cancer Res Treat; 2013 Apr; 138(2):621-31. PubMed ID: 23468242
[TBL] [Abstract][Full Text] [Related]
47. Continuous Intravenous Administration of Granulocyte-Colony-Stimulating Factors-A Breakthrough in the Treatment of Cancer Patients with Febrile Neutropenia.
Căinap C; Cetean-Gheorghe S; Pop LA; Leucuta DC; Piciu D; Mester A; Vlad C; Ovidiu C; Gherman A; Crişan C; Bereanu A; Bălăcescu O; Constantin AM; Dicu I; Bălăcescu L; Stan A; Achimaş-Cadariu P; Căinap S
Medicina (Kaunas); 2021 Jun; 57(7):. PubMed ID: 34208815
[TBL] [Abstract][Full Text] [Related]
48. Guideline for the Management of Fever and Neutropenia in Pediatric Patients With Cancer and Hematopoietic Cell Transplantation Recipients: 2023 Update.
Lehrnbecher T; Robinson PD; Ammann RA; Fisher B; Patel P; Phillips R; Beauchemin MP; Carlesse F; Castagnola E; Davis BL; Elgarten CW; Groll AH; Haeusler GM; Koenig C; Santolaya ME; Tissing WJE; Wolf J; Alexander S; Hu H; Dupuis LL; Sung L
J Clin Oncol; 2023 Mar; 41(9):1774-1785. PubMed ID: 36689694
[TBL] [Abstract][Full Text] [Related]
49. Etiology and clinical course of febrile neutropenia in children with cancer.
Hakim H; Flynn PM; Knapp KM; Srivastava DK; Gaur AH
J Pediatr Hematol Oncol; 2009 Sep; 31(9):623-9. PubMed ID: 19644403
[TBL] [Abstract][Full Text] [Related]
50. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis.
Lee S; Knox A; Zeng IS; Coomarasamy C; Blacklock H; Issa S
Support Care Cancer; 2013 Mar; 21(3):841-6. PubMed ID: 22972488
[TBL] [Abstract][Full Text] [Related]
51. SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018).
Carmona-Bayonas A; Jimenez-Fonseca P; de Castro EM; Mata E; Biosca M; Custodio A; Espinosa J; Vázquez EG; Henao F; Ayala de la Peña F
Clin Transl Oncol; 2019 Jan; 21(1):75-86. PubMed ID: 30470991
[TBL] [Abstract][Full Text] [Related]
52. Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients.
Teuffel O; Cheng S; Ethier MC; Diorio C; Martino J; Mayo C; Wing R; Sung L; Alibhai SM
Support Care Cancer; 2012 Nov; 20(11):2755-64. PubMed ID: 22350594
[TBL] [Abstract][Full Text] [Related]
53. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
54. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.
Ludwig H; Gascón P; Bokemeyer C; Aapro M; Boccadoro M; Denhaerynck K; Krendyukov A; MacDonald K; Abraham I
Support Care Cancer; 2019 Jun; 27(6):2301-2312. PubMed ID: 30343410
[TBL] [Abstract][Full Text] [Related]
55. Therapeutic Use of Filgrastim for Established Febrile Neutropenia Is Cost Effective Among Patients With Solid Tumors and Lymphomas.
Wang XJ; Tong WX; Chan A
Clin Ther; 2017 Jun; 39(6):1161-1170. PubMed ID: 28554533
[TBL] [Abstract][Full Text] [Related]
56. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia.
Rondinelli PI; Ribeiro Kde C; de Camargo B
J Pediatr Hematol Oncol; 2006 Oct; 28(10):665-70. PubMed ID: 17023827
[TBL] [Abstract][Full Text] [Related]
57. Emergency management of fever and neutropenia in children with cancer: A review.
Pulcini CD; Lentz S; Saladino RA; Bounds R; Herrington R; Michaels MG; Maurer SH
Am J Emerg Med; 2021 Dec; 50():693-698. PubMed ID: 34879488
[TBL] [Abstract][Full Text] [Related]
58. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KV; Ramsey SD
J Clin Oncol; 2013 Feb; 31(6):794-810. PubMed ID: 23319691
[TBL] [Abstract][Full Text] [Related]
59. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L
J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839
[TBL] [Abstract][Full Text] [Related]
60. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
